Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1935 1
1951 1
1981 1
1982 2
1984 3
1986 6
1987 2
1988 5
1989 4
1990 6
1991 5
1992 2
1993 3
1994 3
1995 4
1996 2
1997 4
1998 2
1999 3
2000 3
2001 4
2002 3
2003 1
2004 5
2005 4
2006 4
2007 3
2008 10
2009 3
2010 4
2011 5
2012 7
2013 6
2014 8
2015 10
2016 6
2017 15
2018 14
2019 19
2020 27
2021 30
2022 29
2023 29
2024 30
2025 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

335 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Editorial Commentary.
Kronstedt S, Singer EA. Kronstedt S, et al. Among authors: singer ea. Urol Pract. 2024 Sep;11(5):869-870. doi: 10.1097/UPJ.0000000000000627. Epub 2024 Jun 5. Urol Pract. 2024. PMID: 38913562 No abstract available.
Editorial Comment.
Kronstedt S, Singer EA. Kronstedt S, et al. Among authors: singer ea. J Urol. 2024 Jan;211(1):79. doi: 10.1097/JU.0000000000003765.01. Epub 2024 Jan 1. J Urol. 2024. PMID: 38063174 No abstract available.
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Balar AV, et al. Among authors: singer ea. Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051177 Clinical Trial.
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA. Rathmell WK, et al. Among authors: singer ea. J Clin Oncol. 2022 Sep 1;40(25):2957-2995. doi: 10.1200/JCO.22.00868. Epub 2022 Jun 21. J Clin Oncol. 2022. PMID: 35728020
Editorial Comment.
Kronstedt S, Singer EA. Kronstedt S, et al. Among authors: singer ea. Urol Pract. 2023 Nov;10(6):638. doi: 10.1097/UPJ.0000000000000452.02. Epub 2023 Sep 1. Urol Pract. 2023. PMID: 37856720 No abstract available.
Editorial Comment.
Kronstedt S, Singer EA. Kronstedt S, et al. Among authors: singer ea. J Urol. 2025 Jan;213(1):113. doi: 10.1097/JU.0000000000004243. Epub 2024 Sep 27. J Urol. 2025. PMID: 39330871 No abstract available.
Editorial Commentary.
Chua KJ, Mikhail M, Singer EA. Chua KJ, et al. Among authors: singer ea. Urol Pract. 2022 Jul;9(4):348-349. doi: 10.1097/UPJ.0000000000000304.01. Epub 2022 Jun 17. Urol Pract. 2022. PMID: 37145791 No abstract available.
335 results